Launched in 2005, TechnoPhage is an innovative biopharmaceutical company committed to the R&D of new biological molecules in several therapeutic areas, such as infection, neuroscience, and ophthalmology. TechnoPhage’s strategy is based on developing new therapeutics from early discovery to clinical development, including in-house capacity for process development, and GMP production. The company has recently launched its own GMP manufacturing plant specialized in the production of biologics such as bacteriophages and antibody fragments. TechnoPhage is focused on increasing its pipeline of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across Europe, USA, and Asia. The company’s headquarters are located in Lisbon, in close proximity to the renowned Santa Maria Hospital and the Instituto de Medicina Molecular João Lobo Antunes. Overall, the proximity to these valuable partners ensures the access to the necessary equipment, and to the know-how required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.